REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - HC Wainwright lifted their Q1 2025 earnings estimates for REGENXBIO in a research report issued on Monday, March 17th. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will post earnings of ($1.21) per share for the quarter, up from their previous forecast of ($1.35). HC Wainwright has a "Buy" rating and a $34.00 price objective on the stock. The consensus estimate for REGENXBIO's current full-year earnings is ($4.84) per share. HC Wainwright also issued estimates for REGENXBIO's Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.
A number of other research firms have also recently weighed in on RGNX. Royal Bank of Canada restated an "outperform" rating and issued a $30.00 price target on shares of REGENXBIO in a report on Tuesday, January 21st. StockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, March 7th. Morgan Stanley increased their price target on shares of REGENXBIO from $22.00 to $24.00 and gave the stock an "overweight" rating in a research report on Friday, March 14th. Chardan Capital reaffirmed a "buy" rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday. Finally, The Goldman Sachs Group cut shares of REGENXBIO from a "buy" rating to a "neutral" rating and reduced their price target for the stock from $38.00 to $14.00 in a research report on Tuesday, February 11th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $33.88.
Get Our Latest Stock Report on REGENXBIO
REGENXBIO Price Performance
NASDAQ RGNX traded down $0.12 on Wednesday, reaching $8.24. The company had a trading volume of 2,493,911 shares, compared to its average volume of 711,047. The firm has a market capitalization of $412.71 million, a PE ratio of -1.64 and a beta of 1.35. REGENXBIO has a 1 year low of $5.62 and a 1 year high of $22.42. The firm has a 50-day moving average of $7.30 and a 200-day moving average of $8.88.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping analysts' consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million during the quarter, compared to analysts' expectations of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.
Institutional Investors Weigh In On REGENXBIO
A number of hedge funds have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of REGENXBIO in the 3rd quarter worth about $643,000. Intech Investment Management LLC acquired a new stake in shares of REGENXBIO in the 3rd quarter worth about $161,000. Charles Schwab Investment Management Inc. increased its holdings in shares of REGENXBIO by 9.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company's stock worth $4,382,000 after acquiring an additional 37,055 shares during the period. FMR LLC increased its holdings in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 1,656 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of REGENXBIO by 602.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company's stock worth $214,000 after acquiring an additional 17,533 shares during the period. 88.08% of the stock is currently owned by institutional investors.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
See Also
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
